Tevogen Bio Holdings Inc. reported a reduction in its operational losses for the second quarter of 2025. The company announced a loss from operations of $5.4 million for the quarter ended June 30, 2025, a notable improvement compared to the $8.6 million loss reported for the same period in 2024. The net loss for the quarter was $5.5 million, down from $9.7 million in the second quarter of 2024. Tevogen continues to focus on maximizing capital efficiency and has maintained access to financing to support its growth strategies. The company is advancing its infrastructure, artificial intelligence capabilities, and internal strengths in a market experiencing limited growth. It also anticipates generating revenue by the end of 2026 and is actively exploring options to address its limited tradable float to better meet investor demand. In a strategic move, Tevogen is in the process of establishing its own GMP manufacturing facility, which aims to enhance control over its production processes and accelerate product development timelines. Detailed financial results are available in the company's Form 10-Q filed with the SEC.